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Background: Early preclinical diagnosis of COPD is urgent. We proposed that fatty acid composition of red blood
cells may serve as a prognostic test for the complications in the chronic respiratory diseases. Fatty acid composition
of the erythrocyte membranes in patients with chronic respiratory diseases (chronic bronchitis, CB, and stable
chronic obstructive pulmonary disease, COPD) was studied. It was established that modification of the fatty acid
composition in the erythrocyte membranes was unidirectional in both groups of patients.
Methods: Patients with CB and stable COPD (group A, GOLD 1) (15 subjects in each group) were studied in clinic.
The activity of the inflammatory process was evaluated by the phagocytic activity of neutrophils, cytokine levels
and cytokine receptors in the blood serum (TNFα, sTNF-RI, bFGF, TGF-β, IL-8). Fatty acid (FA) composition of the
erythrocyte membranes was analyzed by gas liquid chromatography. Statistical data processing was performed by
the methods of descriptive statistics with Statistica 6.0.
Results: In both groups (CB and COPD), a significant accumulation of the saturated FAs (14:0, 15:0, 18:0) was
established. The amount of the arachidonic acid (20:4n-6) was increased by 13% (р < 0.05) in CB patients and by
41% (р < 0.001) in COPD patients, as compared with healthy persons. The elevated level of the PUFA n-6 in the
erythrocytes membranes in patients with chronic respiratory diseases confirms that proinflammatory (leukotriene
B4) and bronchospasm (prostaglandin D2) mediator substrates is increased. The level of the eicosapentaenoic acid
(20:5n-3) was decreased by 32% (р < 0.05) in CB patients and 2-fold (р < 0.001) in COPD patients. The observed
increase in the 20:4n-6/20:5n-3 ratio - 1.5-fold (р < 0.001) in CB patients and 3-fold in COPD patients - can be a
specific marker of the adverse course of the respiratory pathology and the chronic inflammatory development.
Conclusions: Chronic respiratory disease development is associated with the disturbance of the fatty acid
composition in erythrocyte membranes and disbalance of the ratio between precursor of pro- and
antiinflammatory eicosanoids.
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Diseases of the respiratory system are among the most
common diseases and so present a significant medical
and social problem as the fourth leading cause of mor-
tality [1,2]. Among chronic respiratory diseases, much
attention is paid to chronic obstructive pulmonary dis-
ease (COPD) and chronic bronchitis (CB) [3-5]. From
4% to 15% of total adult population suffer from COPD.
The frequency of chronic bronchitis in different coun-
tries varies in a wide range from 10% to 47% on an aver-
age [1]. The views of the researchers on the relationship
of CB and COPD have been gradually changing with
better understanding of the pathogenesis of these
diseases but still they remain obscure. Earlier, the
symptoms and morphological changes characteristic of
chronic bronchitis were considered as stage 0 or a devel-
oping increased risk of COPD [6]. Later, chronic bron-
chitis was considered as an independent disease which
causes no lung function decline [7]. In recent years, the
researchers have become convinced that chronic bron-
chitis may precede the development of COPD [4]. Pa-
tients with COPD usually ask for medical help only in
the late stages of the disease, when medical treatment
cannot prevent the progression of the disease and the
development of complications. According to this prob-
lem, the possibly early preclinical diagnosis of COPD is
urgent [1,2].
Respiratory diseases are accompanied by the develop-
ment of the chronic inflammatory reaction that greatly
aggravates the course and prognosis of the underlying
disease [8]. The development of the inflammation in the
pulmonary diseases involves also participation of the in-
flammatory mediators (cytokines, histamine, neutral pro-
teases, and eicosanoids) [9-16]. Particular attention is
paid to the lipid mediators - eicosanoids (prostaglandins,
leukotrienes, thromboxanes), which are the final prod-
ucts of the metabolism of polyunsaturated fatty acids
(PUFAs) [11,13,17]. The violation of the membrane FA
composition and FA metabolism is an important factor
in the development of the pulmonary diseases [18,19].
Polyunsaturated fatty acids are on one hand the struc-
tural components of biological membranes [20,21] and
on the other hand they are substrates for synthesis of
eicosanoids [22]. Changes in the FA profile of the lipid
membranes may lead to violation of the aggregation, and
diffusion transfer of membrane components, the activity
of membrane-bound enzymes and the expression of
receptors, the membrane permeability and transport
properties [20,21]. Many functions of immune cells, such
as secretion, chemotaxis, and sensitivity to microorgan-
isms depend also on the fluidity of the membrane [23].
The literature does not sufficiently highlight the qualita-
tive and quantitative composition of FAs of cell mem-
branes in chronic pulmonary diseases. Moreover, theresults of different authors differ significantly, which
may be associated with a variety of biomaterials used for
FA analysis (red blood cells, plasma) and the degree of
clinical severity of the pulmonary disease [24,25]. There
are no available data about possibility of using FA com-
position as a prognostic test for the complications in the
chronic respiratory diseases.
Objective: To assess the fatty acid composition of the
membranes of the red blood cells in patients with




The study involved 40 subjects, 30 of them were pa-
tients with diseases of the bronchopulmonary system
(19 men, 11 women) aged 23–57 years, including 15 pa-
tients with chronic bronchitis (CB) in remission and 15
patients with chronic obstructive pulmonary disease
(COPD) of a stable flow (Group A spirometric, GOLD
class 1). The studies were performed according to
Helsinki Declaration (http://www.wma.net/en/30publi
cations/10policies/b3/index.html). Each subject gave
written informed consent for participating in the study,
which was approved by the ethics committee of Vladi-
vostok Branch of the Far Eastern Center of Physiology
and Pathology of Respiration of SB RAMN - Institute of
Medical Climatology and Rehabilitative Treatment. The
disease was diagnosed on the basis of the medical his-
tory, physical examination, and laboratory tests with
post-bronchodilator spirometry. COPD was diagnosed
according to the “Global Strategy: diagnosis, treatment
and prevention of COPD (GOLD 2011) [1]. Ten healthy
subjects were included in the study as a control group;
they were ex-smokers or nonsmokers without respira-
tory infection within at least the last 4 weeks. Exclusion
criteria were the presence of professional bronchopul-
monary diseases, cardiovascular diseases (coronary
heart disease, hypertensive disease) and their complica-
tions, diabetes, thyroid disease, acute pathological
conditions, and exacerbations of chronic diseases. Spir-
ometry revealed no signs of airflow limitation in
patients with CB. COPD was defined by post-
bronchodilator test FEV1/FVC <70% (ratio of forced
expiratory volume in one second (FEV 1) to forced vital
capacity of lungs (FVC).
Evaluation of the immune system
The immune system was evaluated by the phagocytic ac-
tivity of the neutrophils, the level of the cytokines in the
blood serum. The phagocytic activity of the neutrophils
was studied by the Mayansky method [26]. The receptor
for TNFα, the levels of tumor necrosis factor (TNF RI
(p55), interleukin-8 (IL-8), interleukin-10 (IL-10), the
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growth factor β1 (TGFβ1) were studied in the blood
serum. Cytokine levels were determined by ELISA test
using a kit from «Genzyme Diagnostics». Measurements
were carried out in 96-well flat-bottomed plates with a
Bio-tek Power Wave spectrophotometer (USA).
Determination of the fatty acids in the erythrocyte
membranes
Erythrocyte membranes were prepared by erythrocyte
hemolysis with distilled water, centrifugation for 15 min
at 14000 rev/min in PBS solution with thrice washing.
The red blood cell was taken as a classical model of cell
membranes as well as a universal model for the study of
pathological reactions: e.g. erythrocyte membranes were
used as diagnostic criteria for assessment of different
diseases [27]. Lipids were extracted from the membranes
of the red blood cells using the solvent system chloro-
form – methanol, 1:2 (v/v), and then chloroform-
methanol (1:1 v/v) and 0.9% sodium chloride were added
until a complete phase separation is reached [28]. Fatty
acid methyl esters (FAME) were obtained by a sequential
treatment of the total lipids with 1% sodium methylate/
methanol and 5% HCl/methanol according to Carreau
and Dubacq [29] and purified by preparative silica gel
thin-layer chromatography, using the silica gel plates de-
veloped in benzene. MEFA were analyzed on a Shimadzu
GC-2010 (Japan) gas chromatograph equipped with a
flame ionization detector, using a fused silica capillary col-
umn (Supelcowax-10, 30 m × 0.25 mm i. d. Supelco,
Bellefonte, PA). Helium was used as a carrier gas at a lin-
ear velocity of 30 cms–1. The column temperature was
210 C°, injector and detector temperatures were 250°C.
Fatty acids were identified by a comparison with standard
mixtures and equivalent chain length values [30]. The re-
sults were expressed in relative % of total FAs.
Statistical analysis
Statistical data processing was performed using the
methods of descriptive statistics with Statistica 6.0:
the arithmetic means (M) and the standard error ofTable 1 Indicators of the immune status in patients with chro
Indicators Healthy subjects n = 10 Patient with c
PAN, % 64.52 ± 0.68 5
TNFα, pg/ml 2.60 ± 0.03 7
sTNF-RI, pg/ml 789.1 ± 7.10 159
bFGF, pg/ml 38.3 ± 0.8
TGF-β, pg/ml 1865.4 ± 11.3 14
IL-8, pg/ml 11.5 ± 1.9 1
PAN – phagocytic activity of the neutrophils. Asteriks indicate significant difference
* for р < 0.05; ** for р < 0.01; *** for р < 0.001. Asteriks indicate significant differenc
chronic obstructive pulmonary disease: × for р < 0.001.arithmetic means (m). The differences in contents of the
fatty acids between the patients were tested using a Stu-
dent’s t-test. Differences were considered statistically sig-
nificant at P < 0.05.
Results
The research of the immune status in patients with CB
and COPD revealed the presence of an inflammatory
process (Table 1). The found phagocytic activity of the
neutrophils decrease indicates an inhibition of the non-
specific immune protection factors. The high TNF-α
s-TNFα-RI (p55) value (p<0.001 for all indices) was reg-
istered in patients of both groups, CB and COPD, as
compared with the control group. It is known that the
soluble inhibitor (s-TNFα-RI) promotes long persistence
of the primary proinflammatory cytokine (TNF-α) in the
blood flow and so leads to development of the unstop-
pable chronic inflammation [12]. Patients with CB had
overproduction of the inflammatory mediators compen-
sated by increased IL-8 (p<0.001) with an immunosup-
pressive activity [15,16]. The level of IL-8 in patients
with COPD did not differ from that in the control
group. The level of TGF-β was decreased (p<0.01) in pa-
tients with CB and significantly increased (p < 0.001) in
patients with COPD. Development of COPD was associ-
ated with high values of bFGF (p<0.001). The observed
phagocytic activity of the neutrophils fall on the back-
ground of the increasing phagocytic activity of neutro-
phils in patients with CB (TNF-α, s-TNFα-RI (p55)) and
COPD (TNF-α, s-TNFα-RI (p55), TGF-β) indicates the
development of the chronic inflammatory process [12].
It was found that some saturated fatty acids, such as 12:0
(p <0.01), 14:0 (p <0.01), and 15:0 (p <0.05) were accumu-
lated in erythrocytes of patients with CB, compared to the
control group (Table 2). The relative content of 16:1n-7 in
the erythrocyte membrane increased (p <0.05) in patients
with CB. The relative content of 20:4 n-6 increased by 13%
(p <0.05) compared to healthy individuals. The level of
20:5n-3 decreased by 32% (p <0.05) compared to the con-
trol group. Reduction of the 20:5n-3 level in the erythro-
cyte membrane lead to reduction of the content of itsnic respiratory diseases, mean ± SE
hronic bronchitis, n = 15 Patients with chronic obstructive
pulmonary disease n = 15
9.90 ± 0.88* 57.52 ± 1.96*
.89 ± 1.47*** ×4.3 ± 0.3***
5.58 ± 141.53*** 1523.4 ± 11.0***
38.93 ± 1.54 ×53.9 ± 0.3***
79.17 ± 19.60** ×48145.0 ± 20.6***
7.40 ± 1.20*** ×13.4 ± 1.6
s of indicators between patients with respiratory diseases and healthy subjects:
es of fatty acid contents between patients with chronic bronchitis and with
Table 2 Fatty acid composition of erythrocyte membranes in patients with chronic respiratory diseases, mean ± SE
Fatty acids % Healthy subjects n = 10 Patient with chronic bronchitis n = 15 Patients with chronic obstructive
pulmonary disease n = 15
12:0 0.18 ± 0.01 0.35 ± 0.07**
14:0 0.39 ± 0.03 0.65 ± 0.12** ×××0.34 ± 0.01
15:0 0.17 ± 0.01 0.24 ± 0.04* ×××1.08 ± 0.01***
16:0 23.98 ± 1.28 22.32 ± 1.47 23.16 ± 0.28
16:1n-9 0.21 ± 0.05 0.27 ± 0.03 0.21 ± 0.05
16:1n-7 0.39 ± 0.03 0.51 ± 0.05* 0.53 ± 0.05
17:0 0.35 ± 0.02 0.27 ± 0.03 0.25 ± 0.03
18:0 13.40 ± 0.75 15.27 ± 0.52 16.78 ± 0.40*
18:1n-9 14.84 ± 0.84 14.86 ± 0.45 15.49 ± 0.73
18:1n-7 1.53 ± 0.08 1.33 ± 0.12 ××1.76 ± 0.05
18:1n-5 0.32 ± 0.02 0.33 ± 0.08 0.36 ± 0.14
18:2n-6 15.75 ± 0.28 15.00 ± 0.16 ×××12.21 ± 0.61**
18:3n-3 0.15 ± 0.02 0.22 ± 0.09 ×××0.13 ± 0.03
20:0 0.15 ± 0.035 0.13 ± 0.04 ×××0.46 ± 0.04***
20:1 0.34 ± 0.07 0.27 ± 0.07 0.23 ± 0.03
20:2n-6 0.25 ± 0.005 0.29 ± 0.03 0.26 ± 0.02
20:3n-6 1.59 ± 0.51 1.45 ± 0.17 1.70 ± 0.20
20:4n-6 12.95 ± 1.65 14.89 ± 0.79* ×××18.26 ± 0.50***
20:5n-3 1.23 ± 0.04 0.93 ± 0.09* ×××0.56 ± 0.06***
22:4n-6 2.37 ± 0.29 2.38 ± 0.22 ×3.18 ± 0.31**
22:5n-6 0.37 ± 0.01 0.31 ± 0.04 ×0.46 ± 0.07
22:5n-3 1.99 ± 0.02 1.88 ± 0.03* 1.82 ± 0.05*
22:6n-3 4.67 ± 0.85 6.09 ± 0.60 5.87 ± 0.39
Sum n-6 32.91 ± 0.10 34.32 ± 0.70* 36.07 ± 0.55**
Sum n-3 8.04 ± 0.12 9.12 ± 0.89 8.32 ± 0.42
20:4n-6/20:5n-3 10.52 ± 0.12 16.01 ± 1.3*** 32.60 ± 2.8***
Other fatty acids (10:0, 19:0, 22:0, 14:1, 22:1, 18:2n-5/9, and 20:3n-3) were present in trace amounts (< 0.1%) and are not included into the table.
Asteriks indicate significant differences of fatty acid contents between patients with respiratory diseases and healthy subjects: * for р < 0.05; ** for р < 0.01; *** for
р < 0.001; Asteriks indicate significant differences of fatty acid contents between patients with chronic bronchitis and with chronic obstructive pulmonary disease:
× for р < 0.05; ×× for р < 0.01; ××× for р < 0.001.
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tents of 20:4n-6 and 20:5n-3 lead to a 1.5-fold increase in
the ratio 20:4n-6/20:5n-3 (p <0.001).
The contents of 15:0 (p <0.001) and 18:0 (p <0.05)
20:0 (p <0.001) in patients with COPD increased as
compared to the control group. The relative content of
essential linoleic acid 18:2n-6 reduced (p <0.01). In the
erythrocyte membranes, the level of 20:4n-6 increased
by 41% (p <0.001) as compared to the control group.
The relative contents of 20:5n-3 and its metabolite
docosapentaenoic acid 22:5n-3 in the erythrocytes
decreased, respectively, twice (p <0.001) and by 9%
(p <0.05). The study revealed an accumulation of
22:4n-6 (p <0.001) and a rise of the amount of PUFAs
n-6 by 10% (p <0.01) as compared to the control group.
The ratio of 20:4n-6/20:5n-3 in COPD patients was
3-fold higher (p <0.001) than in the control group.Discussion
The results prove the fact that the fatty acid composition
of the erythrocyte membranes in patients with chronic
respiratory diseases was modified. Moreover, the changes
in the physiologically important FAs in patients with
COPD and CB were unidirectional. The study revealed a
significant accumulation of saturated FAs. Saturated FAs
(in particular palmitic and stearic acids) are the building
components of the lung surfactant [31]. Therefore, an
increased content of FAs with the saturated hydrocarbon
chain in the erythrocyte membranes in patients with
bronchopulmonary diseases might be an advantage. On
the other hand, accumulation of saturated FAs in the cell
membrane increases the rigidity of the lipid bilayer and
so leads to disruption of the structural and functional
characteristics of the cells, to reduction of its fluidity
and membrane-dependent enzyme activity, to inhibition
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cell death mediated by apoptosis or necrosis at mem-
brane destruction [25].
Our study has determined a significant breach in the
PUFA composition. Patients with CB and COPD have
shown an accumulation of 20:4n-6 against a deficiency
of 20:5n-3. An imbalance of these PUFAs in patients
with COPD is more pronounced than in patients with
CB. This fact indicates the aggravation of the FA modifi-
cation in the cell membranes during the COPD develop-
ment. The pathogenic significance of the identified
modifications is determined by the functional role of
lipids in cellular structures. Polyunsaturated FAs per-
form two functions in cells - structural [20,21] and regu-
latory [32,33]. The regulatory function is associated with
the fact that cells utilize PUFAs as precursors of the
synthesis of biologically active substances, eicosanoids.
Eicosanoids locally regulate the function of the
endothelium, smooth muscle cells, the reaction of the
vasodilation, platelet aggregation, microcirculation and
inflammation [22,32]. Arachidonic acid (20:4n-6) and its
metabolite (22:4n-6) are substrates for the biosynthesis
of the eicosanoids, which have inflammatory, chemotac-
tic, and bronchospastic properties [34]. But antiinflama-
tory eicosanoids with a bronchodilation property are
synthesized from eicosapentaenoic acid (20:5n-3) and its
metabolic products (22:5n-3 and 22:6n-3) by cyclooxy-
genase and lipoxygenase reactions [32].
Therefore, a high content of PUFAs of the n-6 family
provides inflammatory component effects on the platelet
aggregation properties, the immune system functioning,
and bronchospasm. The observed increase in the
contents of 20:4n-6 and 22:4n-6 in the erythrocyte
membrane in patients with chronic bronchopulmonary
pathologies indicates an increase of the substrate for
formation of the inflammatory (leukotriene B4) and
bronchoconstriction (prostaglandin D2) mediators [34].
Besides, the high content of arachidonic acid occurs on
the background of a significant deficit of the eicosa-
pentaenoic acid (20:5n-3). These FAs are competitors for
the lipooxygenase and cyclooxygenase enzymes [22,34].
It is known that endogenous deficiency of PUFA n-3 in
cells alters the physico-chemical properties of the plasma
membranes, leads to the receptor malfunction, synthesis
of proinflammatory and bronchoconstrictor eicosanoids,
and to formation of systemic inflammation [18,32]. The
development of the inflammatory response in patients
with respiratory diseases is confirmed by the identified
imbalance between proinflammatory cytokines and low
phagocytic activity of the neutrophils. An increased ratio
of 20:4n-6/20:5n-3 which indicates violations in the
eicosanoid cycle and the predominance of the synthesis
of proinflammatory mediators, became a significant fac-
tor of the increased risk of the complication andaggravation of the respiratory pathology. Consequently,
the increased 20:4n-6/20:5n-3 ratio can be a specific
marker of an unfavorable course of bronchopulmonary
diseases. Early detection of violations of the FA compos-
ition in patients with respiratory diseases and an
adequate correction of these disorders can prevent the
development of a more severe pulmonary disease.
Conclusions
Thus, the study has shown that the development of the
chronic respiratory diseases is accompanied by the
breach of the fatty acid composition of the erythrocyte
membrane. Modification of the fatty acid composition in
the membranes of the red blood cells in patients with
chronic pulmonary diseases not only leads to disruption
of the cell structure skeleton but also to violation of the
regulation of the immune response. It is possible that
disruption of the lipid components of the cell membrane
causes development of the inflammatory process, which
is involved in the pathogenesis of chronic bronchitis and
chronic obstructive pulmonary disease. Further research
is needed to study the metabolism of the fatty acids and
eicosanoid formation activity in the respiratory diseases.
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